Skip to main content
main-content

Prediabetes & diabetes prevention


Browse the latest news, expert commentary, and educational content on prediabetes and diabetes prevention.


03-05-2021 | Teplizumab | News

Teplizumab offers extended preservation of beta-cell function

Prolonged follow-up of high-risk people treated with teplizumab to prevent progression to type 1 diabetes shows a lasting beneficial effect on beta-cell function, say researchers.

03-02-2021 | Epidemiology | News

Signs of slowing diabetes incidence in higher-income countries

The incidence of diabetes in high- and middle-income countries may at last be stabilizing, or even in decline, say researchers.

02-23-2021 | Diabetes prevention | News

Stabilizing IGT for a time has significant long-term vascular benefits

Delaying progression from impaired glucose tolerance to type 2 diabetes reduces the risk for micro- and macrovascular complications, shows 24 years of follow-up of the Da Qing trial.

02-09-2021 | Older adults | News

Prediabetes a poor predictor of outcomes in older adults

Adults who develop prediabetes when older than 70 years are more likely to regress to normoglycemia or die of other causes than to progress to type 2 diabetes, research shows.

01-28-2021 | Diabetes prevention | News

Dapagliflozin may reduce diabetes risk in people with heart failure

Use of the SGLT2 inhibitor dapagliflozin is associated with a reduced risk for new-onset type 2 diabetes in high-risk individuals with heart failure and reduced ejection fraction, suggests an exploratory analysis of data from the DAPA-HF trial.

12-21-2020 | Medications | News

Testosterone promising for diabetes prevention pending safety clarification

A randomized trial indicates that testosterone treatment among men with prediabetes or newly diagnosed type 2 diabetes significantly reduces the risk for them having type 2 diabetes 2 years later.

11-17-2020 | Empagliflozin | News

Favorable LV remodeling may contribute to empagliflozin benefits

The SGLT2 inhibitor empagliflozin may reverse adverse left ventricular remodeling in people who have heart failure with reduced ejection fraction and type 2 diabetes or prediabetes, shows a randomized trial.

11-12-2020 | Diabetes prevention | News

Randomized type 2 diabetes prevention trial addresses knowledge gap

Lifestyle intervention significantly reduces the risk for type 2 diabetes in people who have prediabetes based on fasting plasma glucose or glycated hemoglobin measurements, show findings from a randomized trial.

07-21-2020 | Cardiovascular outcomes | News

Sex differences in MI risk in type 2 diabetes explored

The excess risk for myocardial infarction associated with having diabetes may be greater in women than men, despite men having a higher frequency of events overall, shows research from the UK Biobank.

07-17-2020 | Prediabetes | News

Updated meta-analysis confirms prediabetes link with mortality, CVD risk

Prediabetes is associated with an elevated risk for all-cause mortality and cardiovascular events, both in the general population and in patients with atherosclerotic cardiovascular disease, shows an updated meta-analysis published in The BMJ.

07-10-2020 | Prediabetes | Highlight | News

Key danger times identified for US Diabetes Prevention Program dropout

Focusing efforts on convincing people to return after the first session of the US National Diabetes Prevention Program lifestyle change program, and after the transition to less frequent sessions, may help to optimize program retention, say researchers.

07-02-2020 | Prediabetes | Highlight | News

Neighborhood walkability may reduce ethnic disparities in diabetes risk

The increased risk for prediabetes among ethnic minorities compared with White people is less pronounced in neighborhoods with high walkability, shows a Canadian study.

06-24-2020 | ADA 2020 | Conference coverage | News

More studies show potential for slowing type 1 diabetes progression

Several therapies aimed at slowing the progression of early type 1 diabetes show promise in research presented at the virtual 80th ADA Scientific Sessions.

06-16-2020 | ADA 2020 | Conference coverage | News

DPPOS: No change to cancer risk with long-term metformin use

Among the latest findings from the DPP Outcomes Study is that long-term use of metformin does not affect the risk for cancer.

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits